Nathalie Bonnefoy

Biography

  Cell tumorigenesis comprises multiple steps, including genetic and epigenetic changes that drive the progressive transformation of normal cells into highly malignant derivatives. However it is now clearly established that the development of tumors is strongly influenced by the host’s immune system, which can partly control the behavior of primary cancer cells and has a strong impact on patients’ response to chemo and radiotherapy-based treatments.   Thus strengthening/reinvigorating the tumor immune surveillance by stimulating rejection-type processes or blocking suppressive pathways is the foundation of new immune-based therapies that allow the development of a long-lasting adaptive immunity, which counteracts tumor growth and prevents tumor relapse.    In this context, the research programs developed in our group aim at a better understanding of the relationships between cancer cells and cells of the immune system. With a specific interest in:   - The contribution of adaptive immunity effectors to the prevention or treatment of cancer   - The role of mediators of inflammation in the development of cancer   Our projects are established on our expertise in onco-immunology with a strong knowledge of preclinical models and a recognized expertise of tumor immune microenvironment analysis. They are developed in close association with clinicians and industrial partners.

Research Interest

 oncology